Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUTABARBITAL SODIUM vs BUTABARBITAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Depresses neuronal activity in the reticular activating system by enhancing GABA-A receptor-mediated chloride influx, increasing the duration of chloride channel opening and inhibiting excitatory neurotransmission at high doses.
Butabarbital is a barbiturate that acts as a central nervous system depressant. It enhances the activity of GABA, an inhibitory neurotransmitter, by binding to the GABA-A receptor and prolonging the opening of chloride ion channels, leading to neuronal hyperpolarization and reduced excitability.
Preoperative sedation,Daytime sedation,Insomnia (short-term treatment),Status epilepticus (adjunct),Withdrawal syndrome (off-label)
Sedative,Hypnotic for short-term treatment of insomnia,Preoperative sedation
Sedative: 15-30 mg orally 3-4 times daily. Hypnotic: 50-100 mg orally at bedtime. Maximum single dose: 100 mg. Maximum daily dose: 300 mg. Route: oral, intramuscular, intravenous. For IM/IV: divide oral dose by 2.
50-100 mg orally or intramuscularly 3-4 times daily; maximum 400 mg/day.
Terminal elimination half-life: 30-50 hours; accumulates with repeated dosing, prolonged in hepatic impairment
Terminal elimination half-life is 30-50 hours in adults, which may be prolonged in elderly or patients with hepatic impairment, leading to accumulation with repeated dosing.
Primarily hepatic via CYP2C9, CYP2C19, and CYP3A4; conjugated with glucuronic acid; excreted renally.
Hepatic metabolism via cytochrome P450 enzymes (primarily CYP2C9 and CYP3A4); undergoes hydroxylation and glucuronidation; active metabolites include hydroxybutabarbital.
Renal: 50-70% as metabolites (hydroxylated and conjugated forms), 5-10% unchanged; fecal: minor (<5%)
Primarily renal, with approximately 60-80% of the dose eliminated as metabolites (mostly hydroxylated and conjugated) and less than 5% as unchanged drug. Minor biliary/fecal excretion occurs (<10%).
25-35%, primarily to albumin
Approximately 20-25% bound to plasma proteins, predominantly albumin.
0.5-0.8 L/kg; distributes widely into tissues, crosses blood-brain barrier
Approximately 1.0 L/kg, indicating distribution throughout total body water and extensive tissue binding.
Oral: 80-100% (rapid absorption); IM: complete
Oral bioavailability is nearly 100% (50-70% reported in some texts, but butabarbital is completely absorbed; first-pass metabolism is minimal).
Contraindicated in severe renal impairment (e GFR <30 m L/min). For e GFR 30-50 m L/min: reduce dose by 25% and monitor for CNS depression. e GFR >50 m L/min: no adjustment.
GFR 10-50 m L/min: reduce dose by 25%; GFR <10 m L/min: reduce dose by 50%.
Contraindicated in Child-Pugh Class C. Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75% or use alternative. Avoid in severe hepatic impairment.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use.
Not recommended for children <6 years. For children 6-12 years: sedative 5-15 mg orally 3-4 times daily; hypnotic not typically used. For adolescents >12 years: adult dosing with caution. Maximum single dose: 30 mg. Weight-based: 2-3 mg/kg/day divided every 6-8 hours, not to exceed 100 mg/day.
Children 2-6 years: 25-50 mg orally 3-4 times daily; children 6-12 years: 50-100 mg orally 3-4 times daily; maximum 200 mg/day.
Start with lowest effective dose (e.g., 15 mg orally for sedation). Maximum dose: 50 mg per dose. Caution due to increased sensitivity, risk of falls, and cognitive impairment. Avoid hypnotic use. Consider non-barbiturate alternatives.
Initiate at 25-50 mg orally 3 times daily; increase cautiously to avoid excessive sedation and falls, maximum 200 mg/day.
Barbiturates are habit-forming. Tolerance, psychological and physical dependence may occur. Withdrawal symptoms include delirium, convulsions, and death. Abrupt cessation after prolonged use is not recommended.
Butabarbital has no FDA boxed warning.
Respiratory depression risk; use caution in hepatic impairment, renal impairment, elderly, or debilitated patients; avoid abrupt discontinuation; may cause paradoxical excitement; monitor for hypersensitivity reactions.
Risk of dependence, tolerance, and withdrawal symptoms upon discontinuation; respiratory depression, especially with high doses or in patients with respiratory compromise; CNS depression may impair ability to drive or operate machinery; concomitant use with other CNS depressants (e.g., alcohol, opioids) increases risk of profound sedation and respiratory depression; geriatric patients may be more sensitive to effects; use with caution in patients with hepatic or renal impairment.
Hypersensitivity to barbiturates, porphyria, severe respiratory disease, severe hepatic impairment, history of addiction to sedative-hypnotics.
Hypersensitivity to barbiturates; porphyria (can exacerbate); severe respiratory insufficiency; history of addiction to sedative-hypnotics; acute or chronic pain (may cause paradoxical excitement); pregnancy (especially third trimester) and lactation.
Avoid grapefruit juice as it may alter metabolism. Limit or avoid alcohol; concurrent use increases CNS depression risk. Take with food if GI upset occurs; avoid high-fat meals as they may slow absorption.
Grapefruit juice may decrease metabolism of butabarbital; avoid concurrent consumption. Alcohol increases CNS depression and should be avoided. No specific food restrictions otherwise.
First trimester: Increased risk of major malformations, particularly oral clefts (odds ratio 2.0-3.0). Second trimester: Risk of neural tube defects and cardiac anomalies. Third trimester: Neonatal withdrawal syndrome, respiratory depression, and hemorrhagic disease due to vitamin K deficiency. FDA Category D.
First trimester: Associated with increased risk of major congenital malformations, specifically oral clefts (relative risk ~2.0). Second/third trimester: Chronic use may lead to fetal dependence and withdrawal syndrome; neonatal respiratory depression if used near term; increased risk of neurobehavioral effects. Barbiturates cross the placenta rapidly.
Excreted in breast milk; M/P ratio estimated 0.3-0.5. Risk of infant sedation, poor feeding, and withdrawal. Contraindicated in breastfeeding unless essential. Monitor for drowsiness, weight gain, and developmental milestones.
Butabarbital is excreted into breast milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.4–0.6. With therapeutic doses, infant serum levels are usually low; however, chronic high maternal doses may cause sedation or withdrawal in the nursing infant. Caution is recommended; alternate agents may be preferred if infant sedation occurs.
Increased clearance (up to 50% higher) in pregnancy, especially third trimester. Dose may need to be increased by 30-50% to maintain therapeutic effect. Monitor serum levels and adjust to minimum effective dose.
Pregnancy can alter butabarbital pharmacokinetics due to increased hepatic metabolism and volume of distribution. Serum concentrations may decrease; therapeutic drug monitoring is recommended if used chronically. Dose adjustments may be necessary to maintain efficacy, but due to risks, use is generally avoided. If used, start with lowest effective dose and monitor for clinical response and toxicity.
Barbiturate with rapid onset used for preoperative sedation and seizure control. Respiratory and CNS depression risk is dose-dependent; avoid in porphyria. Tolerance develops with prolonged use; withdrawal can be life-threatening. Use as second-line for status epilepticus after benzodiazepines. Highly protein-bound; monitor for interactions with warfarin and oral contraceptives.
Butabarbital is a short-acting barbiturate with rapid onset. It is primarily used for sedation and insomnia but has high abuse potential. Avoid use in patients with porphyria, severe hepatic impairment, or respiratory insufficiency. Abrupt discontinuation after prolonged use may precipitate withdrawal including seizures. Barbiturates induce CYP3A4 and other hepatic enzymes, reducing efficacy of oral contraceptives, warfarin, and corticosteroids. Use with caution in elderly due to increased risk of falls and cognitive impairment.
Take exactly as prescribed; do not increase dose or frequency.,Avoid alcohol and other CNS depressants (e.g., opioids, benzodiazepines).,Do not drive or operate machinery until you know how this drug affects you.,Do not stop suddenly; abrupt discontinuation can cause withdrawal seizures.,Inform your doctor if you have a history of porphyria, liver disease, or depression.,Use effective contraception; this drug may reduce hormonal contraceptive efficacy.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not stop taking suddenly as withdrawal reactions such as anxiety, tremors, or seizures can occur.,May cause drowsiness or dizziness; do not drive or operate machinery until you know how this medicine affects you.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, opioids) as they increase risk of severe sedation and respiratory depression.,Use effective contraception while taking this medication as it may reduce hormonal contraceptive effectiveness.,Store in a secure place away from children and others, as it can cause dependence and is habit-forming.
"Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects."
"Butabarbital, a barbiturate, is a potent CNS depressant that acts primarily by potentiating GABA-A receptor activity. Metaxalone is a centrally acting muscle relaxant with sedative properties. Coadministration results in additive or synergistic CNS depression, leading to increased risk of excessive sedation, respiratory depression, impaired psychomotor function, and potential coma or death, especially at higher doses or in vulnerable patients."
"Butabarbital, a barbiturate sedative-hypnotic, induces hepatic cytochrome P450 enzymes, particularly CYP3A4, which are responsible for metabolizing the atypical antipsychotic paliperidone. This induction decreases plasma concentrations of paliperidone, potentially reducing its therapeutic efficacy in treating schizophrenia or bipolar disorder. Concomitant use may lead to relapse of psychiatric symptoms or necessitate dose adjustments."
"Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects."
"Butabarbital, a barbiturate, is a potent CNS depressant that acts primarily by potentiating GABA-A receptor activity. Metaxalone is a centrally acting muscle relaxant with sedative properties. Coadministration results in additive or synergistic CNS depression, leading to increased risk of excessive sedation, respiratory depression, impaired psychomotor function, and potential coma or death, especially at higher doses or in vulnerable patients."
"Butabarbital, a barbiturate sedative-hypnotic, induces hepatic cytochrome P450 enzymes, particularly CYP3A4, which are responsible for metabolizing the atypical antipsychotic paliperidone. This induction decreases plasma concentrations of paliperidone, potentially reducing its therapeutic efficacy in treating schizophrenia or bipolar disorder. Concomitant use may lead to relapse of psychiatric symptoms or necessitate dose adjustments."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUTABARBITAL SODIUM vs BUTABARBITAL, answered by our medical review team.
BUTABARBITAL SODIUM is a Barbiturate that works by Depresses neuronal activity in the reticular activating system by enhancing GABA-A receptor-mediated chloride influx, increasing the duration of chloride channel opening and inhibiting excitatory neurotransmission at high doses.. BUTABARBITAL is a Barbiturate that works by Butabarbital is a barbiturate that acts as a central nervous system depressant. It enhances the activity of GABA, an inhibitory neurotransmitter, by binding to the GABA-A receptor and prolonging the opening of chloride ion channels, leading to neuronal hyperpolarization and reduced excitability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUTABARBITAL SODIUM and BUTABARBITAL depend on the specific clinical indication. These are both Barbiturate agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUTABARBITAL SODIUM is: Sedative: 15-30 mg orally 3-4 times daily. Hypnotic: 50-100 mg orally at bedtime. Maximum single dose: 100 mg. Maximum daily dose: 300 mg. Route: oral, intramuscular, intravenous. For IM/IV: divide oral dose by 2.. The standard adult dose of BUTABARBITAL is: 50-100 mg orally or intramuscularly 3-4 times daily; maximum 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining BUTABARBITAL SODIUM and BUTABARBITAL. Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. BUTABARBITAL SODIUM is classified as Category C. First trimester: Increased risk of major malformations, particularly oral clefts (odds ratio 2.0-3.0). Second trimester: Risk of neural tube defects and cardiac anomalies. Third tr. BUTABARBITAL is classified as Category C. First trimester: Associated with increased risk of major congenital malformations, specifically oral clefts (relative risk ~2.0). Second/third trimester: Chronic use may lead to fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.